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I M M U N O L O G Y
Inhibition of the NLRP3 inflammasome prevents 
ovarian aging
José M. Navarro-Pando1*, Elísabet Alcocer-Gómez2*, Beatriz Castejón-Vega3,  
Elena Navarro-Villarán4,5, Mónica Condés-Hervás1, María Mundi-Roldan1, Jordi Muntané4,5,6, 
Antonio J. Pérez-Pulido7, Pedro Bullon3, Chun Wang8, Hal M. Hoffman9, Alberto Sanz3, 
Gabriel Mbalaviele8, Bernhard Ryffel10,11, Mario D. Cordero1,12†
Inflammation is a hallmark of aging and is negatively affecting female fertility. In this study, we evaluate the role 
of the NLRP3 inflammasome in ovarian aging and female fertility. Age-dependent increased expression of NLRP3 
in the ovary was observed in WT mice during reproductive aging. High expression of NLRP3, caspase-1, and IL-1 
was also observed in granulosa cells from patients with ovarian insufficiency. Ablation of NLRP3 improved the 
survival and pregnancy rates and increased anti-Müllerian hormone levels and autophagy rates in ovaries. 
Deficiency of NLRP3 also reduced serum FSH and estradiol levels. Consistent with these results, pharmacological 
inhibition of NLRP3 using a direct NLRP3 inhibitor, MCC950, improved fertility in female mice to levels comparable 
to those of Nlrp3−/− mice. These results suggest that the NLRP3 inflammasome is implicated in the age-dependent 
loss of female fertility and position this inflammasome as a potential new therapeutic target for the treatment of 
infertility.
INTRODUCTION
Aging is a natural process in all animals involving a progressive im-
pairment of physiological and metabolic homeostasis characterized 
by many changes in body composition, insulin resistance, mito-
chondrial and autophagy dysfunction, inflammation, and hormonal 
dysregulation (1). From a clinical point of view, aging is associated 
with many signs of illness such as cardiovascular, neurodegenera-
tive, and metabolic disorders, which are known as age-dependent 
diseases. These pathologies can be managed by different strategies 
including pharmacological intervention, lifestyle modifications, and 
prevention of harmful environmental exposures. However, the 
ovarian aging process is currently a pharmacologically uncontrol-
lable process that impairs female fertility; the infertility correlates 
with a rapid decline after age 35 and is attributable to the impairment 
of the quantity and/or the quality of oocytes (2). Female infertility is 
exacerbated by socioeconomic changes in developed countries, 
which enable women to progressively delay the age at which they 
have their first child. As a consequence, there is increased demand 
for the treatment of infertility (3). One of the key events that con-
tribute to ovarian aging includes follicular atresia as it is associated 
with the breakdown of the ovarian follicles in both physiological and 
premature ovarian aging (2). Follicular atresia, as an associated event 
to cellular aging, show many pathophysiological alterations associ-
ated with physiological aging such as mitochondrial dysfunction, 
oxidative stress, and inflammation, and as aging itself, it is sensitive 
to stress (1–3).
Although inflammation can negatively affect female fertility (4), 
the underlying molecular mechanisms are poorly understood. Pre-
liminary studies in animal models have shown that genetic deletion 
of tumor necrosis factor (TNF) receptor improves female fertility 
and deletion of interleukin-1 (IL-1) mice has prolonged the life 
span of the ovaries (5, 6).
The NLR family pyrin domain containing 3 (NLRP3) inflam-
masome is one of the most well-studied inflammasomes in humans and 
mice (1). It is a multiprotein complex comprising NLRP3 itself as an 
intracellular sensor, the adapter protein ASC [apoptosis-associated 
speck-like protein containing a CARD (caspase recruitment domain)], 
and procaspase-1. Two steps are required for the activation of this 
protein platform. The first step, also known as priming signals, causes 
the transcription of inflammasome constituents, a response that is 
mediated by nuclear factor B and other pathways such as p38 mitogen- 
activated protein kinase (7). Signal two, or triggering, is induced by 
pathogen-associated molecular patterns, and stress- associated signals 
or host-derived damage-associated molecular patterns lead to NLRP3 
oligomerization complex assembly (8), and caspase-1 activation 
activated caspase-1 of caspase-1 process pro–IL-1 and pro–IL-18 
to IL-1 and IL-18, respectively. This inflammasome is also in-
volved in the processing of the pore-forming protein gasdermin D 
whose excessive pore formation can cause an inflammatory form of 
cell death known as pyroptosis (8). The NLRP3 inflammasome is ac-
tivated by a range of danger and stress signals (8), some of which rise 
during aging (1). Thus, NLRP3 inflammasome can contribute to a 
vicious cycle of low-grade inflammation that occurs during aging.
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Genetic deletion of Nlrp3 in mice has been shown to improve 
life span and health by attenuating multiple age-related degenera-
tive changes such as cardiac aging, insulin sensitivity with glycemic 
control, and bone loss (9, 10). However, the role of the NLRP3 
inflammasome in ovarian aging and female age-related fertility 
decline has not been studied. Therefore, we sought to determine 
whether genetic deletion of NLRP3 could have an effect on ovarian 
aging and potentially prevent the decline of female fertility.
RESULTS
The NLRP3 inflammasome is activated during ovarian aging
To evaluate the role of the NLRP3 inflammasome in ovarian aging, 
we examined ovaries from female mice of different ages. Wild-type 
(WT) C57BL/6J female mice exhibited a substantial increase in 
body weight over a 12-month period (Fig. 1A) and a significant de-
crease in anti-Müllerian hormone (AMH) after the sixth month of 
life (Fig. 1B). NLRP3 protein expression was increased from the 
fourth month alongside the levels of active caspase-1 (p20) and an 
age-dependent increase of active IL-1 (p17; Fig. 1, C and D). 
NLRP3 expression was observed in the cytoplasm of granulosa cells 
(GCs) and follicles of different status including atretic follicles, in 
the cytoplasm of oocytes, and in the glandular epithelium of the 
uterus (Fig. 1E, negative control and magnification in figs. S1 to S3). 
Notably, NLRP3 expression in these tissues was higher in aged ani-
mals. NLRP3 expression was inversely correlated with serum AMH 
levels (Fig. 1F). Since autophagic dysfunction has also been linked to 
aging, we analyzed the expression of the components in this pathway. 
We observed an increase in the expression of microtubule-associated 
protein 1 light chain 3 (LC3-II) and other proteins involved in clearance 
pathways such as p62/SQSTM beginning at 6 months (Fig. 1, C and D).
To translate our murine studies to humans, we evaluated NLRP3 
inflammasome activation in GCs from human patients with accel-
erated ovarian aging disease. Diminished ovarian reserve (DOR) is 
a critical fertility defect characterized by an anticipated impairment 
of the follicular reserve for which pathophysiological mechanisms 
are not understood. Different genetic and molecular alterations have 
been proposed, such as mutations in genes associated with DNA 
repair or meiosis, bioenergetics alterations, and mitochondrial 
dysfunction (2). The clinical characteristics of patients with DOR 
and controls are listed in table S1, and low ovarian reserve was 
confirmed by transvaginal ultrasound. Patients with DOR showed 
altered hormonal status compared to the control group (table S1). 
Follicle-stimulating hormone (FSH) levels in these patients were 
above 10 mUI/ml, and estradiol (E2; a sexual hormone involved in 
the regulation of the estrous and menstrual female reproductive 
cycles) levels were above 60 pg/ml. We found significantly increased 
NLRP3 mRNA and protein expression in GCs from patients with 
DOR compared to healthy controls. We also observed elevated 
protein expression of active caspase-1 (p20) and IL-1 (p17) 
(Fig. 1, G and H). However, plasma levels of TNF-, but not IL-1 
and IL-18, were increased in patients with DOR compared to healthy 
controls (table S1).
NLRP3 expression correlates with reproductive aging
To evaluate the impact of NLRP3 expression on female fertility 
during aging, we monitored the life span and reproductive capacity 
of Nlrp3−/− and WT littermates. Kaplan-Meier survival curve showed 
an increase in mean life span of 37% and maximum life span of 24% 
in Nlrp3−/− (Fig. 2A), whereas body weights did not differ between 
both groups (Fig. 2B). Twelve-month-old female Nlrp3−/− mice exhibited 
a significant decrease in glucose serum levels at the Oral glucose 
tolerance tests (OGTT) peak (>15 min) compared to old WT mice 
(fig. S4A), indicating a higher glucose tolerance consistent with a 
trend toward lower values of the area under the curve of the glucose 
tolerance test (fig. S4B). Furthermore, 12-month-old female Nlrp3−/− 
mice showed no significant difference in serum levels of leptin 
compared to WT but an increased level of adiponectin (fig. S4, C 
and D). Twenty eight-month-old WT animals displayed increased 
age-related alopecia compared to Nlrp3 knockout (KO) mice (Fig. 2C). 
AMH serum levels were similar in 2-month-old WT and Nlrp3−/− 
mice but were afterward significantly higher in mutant mice com-
pared to WT mice (Fig. 2D). Consistent with serum levels, ovarian 
AMH protein levels were higher in aged (12 months old) Nlrp3−/− 
mice compared to WT mice (Fig. 2D). In addition, the levels of the 
sex hormones E2 and FSH increased between 4 and 12 months in 
WT mice but not in Nlrp3−/− mice (Fig. 2, E and F). The WT group 
showed a markedly enlarged uterine size and weight (hypertrophic 
uterus) compared to Nlrp3−/− (Fig. 2G). We also analyzed the num-
ber of ovarian follicles by histological staining in ovaries from 
4- and 12-month-old Nlrp3−/− mice, and they showed more dy-
namic activity at 12 months and a greater percentage of follicles at 4 
and 12 months compared with WT mice. Nlrp3−/− ovaries retained 
a larger pool of follicles, which appeared more active in follicu-
logenesis and contained many corpora lutea, observations sug-
gesting successful ovulation (Fig. 2, H and I).
A significant reduction of the pregnancy rate was observed in 
WT mice during aging but was markedly preserved in aged 
(12-month-old) Nlrp3−/− mice compared with WT mice (Fig. 3A). 
These observations were consistent with AMH and ovary data. 
Mean litter size was also significantly larger in 12-month-old 
Nlrp3−/− mice compared with littermate mice as in young mice 
(4 months; Fig. 3B). The loss of the ASC, which has a pivotal role in 
the assembly of several inflammasomes (8), did not affect the age- 
dependent loss of female fertility. Asc−/− mice showed similar levels 
of AMH, FSH, and E2 during aging and reduced AMH protein ex-
pression (fig. S5, A to C). The pregnancy rate and mean litter size in 
Asc−/− mice were not statistically different compared with WT mice 
(fig. S5, D and E). These observations suggest that NLRP3 attenu-
ates the process of ovarian aging independent of ASC expression. 
To reinforce the role of NLRP3 in female fertility, we studied the 
effects of a gain-of-function NLRP3 mutant associated with neona-
tal-onset multisystem inflammatory disease (NOMID) in mice (11), 
which showed data consistent with infertility (fig. S6, A to D).
Age-related autophagic and apoptotic changes 
in the ovaries are prevented by Nlrp3 ablation
Blockade of autophagic flux and accumulation of nondegraded sub-
strates in the form of autophagosome are linked to aging (12). Fur-
thermore, apoptosis and autophagy are involved in the process of 
oocyte loss (13, 14). Nlrp3−/− female mice showed increased levels of 
ATG12, beclin 1, and LC3-II protein and reduced expression of p62/
SQSTM1 compared with an accumulation of LC3-I with p62-aged WT 
mice associated with an impairment of autophagy (Fig. 3C). Apoptosis 
has been associated with ovary aging and inflammation (6). The expres-
sion of the proapoptotic protein BCL2-associated X protein (BAX) was 
also substantially lower in 12-month-old Nlrp3−/− ovaries compared 
with WT ovaries despite no significant changes in the antiapoptotic 
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Fig. 1. NLRP3 signaling is associated with ovarian aging. (A) Body weight progression of female C57BL6/J mice evaluated per month. (B) Mean serum AMH levels to 
evaluate the progression of ovarian reserve during aging. N = 8 per group. (C and D) Western blot analysis with representative blots including NLRP3, caspase-1, IL-1, 
LC3, and p62 levels in the ovary of WT mice at different ages. Densitometric analysis is shown as mean ± SD, n = 10 mice; *P < 0.05, **P < 0.005, and ***P < 0.001; 2 months 
old versus other ages. N = 6 to 8 per group. (E) Immunofluorescence (IF) visualization of NLRP3 (green) and nuclei (blue) in ovary and uterus tissues from young and old 
WT mice. Oocyte (asterisk), GCs (arrows), corpus luteum (CL), and follicular atresia (FA). DAPI, 4′,6-diamidino-2-phenylindole. (F) Correlation of NLRP3 expression versus 
serum AMH levels during aging. The correlation was established by calculating correlation coefficients. (G) Human NLRP3 transcript expression levels were determined 
in GCs by real-time quantitative reverse transcription polymerase chain reaction (PCR); n = 20 for control and n = 20 for DOR groups. (H) Western blot analysis with repre-
sentative blots including NLRP3, caspase-1, and IL-1 levels in GCs from four representative patients with DOR compared to four representative age-matched controls. 
Densitometric analysis is shown as mean ± SD. *P < 0.05, **P < 0.005, and ***P < 0.001; control versus patients.
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protein B-cell lymphoma 2 (BCL-2) (Fig. 3C). Despite reduced levels of 
IL-1 and IL-18 and no differences in the levels of the other inflam-
masomes between 12-month-old Nlrp3−/− ovaries compared to WT (fig. S7, 
A and B), we observed higher levels of TNF and IL-6 in the ovaries of 
mutant mice (fig. S7C). These results suggest that the loss of NLRP3 has a 
role in the reproductive aging independent of other inflammatory pathways.
Age-associated change of ovary gene expression profile 
was prevented in Nlrp3−/− mice
We performed a microarray expression profiling of WT and 
Nlrp3−/− to identify the molecular mechanisms underlying the pre-
served health of the ovaries in 12-month-old mutant mice. There 
were 1453 differentially expressed transcripts between Nlrp3−/− and 
WT mice: 691 transcripts were up-regulated, and 762 transcripts 
were down-regulated (with cutoffs of fold change ≥ 2 and P < 0.05). 
To find the affected biological processes, we used Kyoto Encyclo-
pedia of Genes and Genomes (KEGG) pathway as the annotation 
source. This enrichment analysis revealed that overexpressed genes 
in Nlrp3−/− samples belonged to the following pathways: “cell cycle,” 
“oocyte meiosis,” “progesterone-mediated oocyte maturation,” 
“PI3K-AKT signaling pathway,” “mismatch repair,” and “biosyn-
thesis of amino acids” (Fig. 4A). Consistent with the knowledge that 
aging is associated with a decrease in the efficiency of repair and 
accumulation of DNA damage (15, 16), genes involved in mismatch 
repair pathways were up-regulated in old Nlrp3−/− ovaries (Fig. 4A). 
These results suggest delayed cellular senescence and increased 
capacity of oocytes for DNA repair in mutant ovaries (17). To re-
inforce this concept, the expression value of the genes involved in 
these pathways was further analyzed. Genes associated with the fol-
licle development (e.g., BMP15 and Pla2g4a), ovarian responses to 
hormones (e.g., Fshr), or meiotic M phase (e.g., AURKA and Bub1) 
were up-regulated in all replicates (Fig. 4B). Other interesting 
changes were the up-regulation of Cyclin B1 (Ccnb1) and Ccnb2, which 
are required for embryo development and ovulation of mature 
oocytes, respectively. All these changes indicate an improved meiosis 
pathway and oocyte maturation in Nlrp3−/− mice during aging.
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Pharmacological inhibition of NLRP3 rescues female fertility 
during aging
We tested the effect of the NLRP3 inhibitor, MCC950, in female 
mice. Because fertility in mice declines around 8 months of age, we 
treated 8-month-old mice with vehicle and MCC950 [20 mg/kg per 
day, intraperitoneally (ip)] for 12 weeks. No significant changes in 
body weight were observed between both groups (Fig. 5A). Vehicle- 
treated mice showed significantly reduced AMH serum levels com-
pared to MCC950-exposed mice (Fig. 5B). Serum levels of FSH and 
E2 were also decreased by MCC950 treatment (Fig. 5, C and D), 
findings that were consistent with histological staining showing 
higher percentages of follicles and lower percentages of atretic folli-
cles in MCC950-treated compared to vehicle-administrated mice 
(Fig. 5, E and F). These data revealed a gradual decline in female 
fertility in vehicle-treated mice, whereas age-matched mice in the 
MCC950-treated group remained fertile. The pregnancy rate was 
markedly increased in MCC950-treated mice compared to the vehi-
cle group (Fig. 5G), although differences in the mean litter size were 
not observed (Fig. 5H).
In line with data from Asc−/− mice in which we observed an 
independent effect of the NLRP3 inhibition, we also analyzed the 
effects of 16673-34-0, an intermediate substrate produced during 
glyburide synthesis, which was shown to inhibit NLRP3 inflam-
masome complex formation by interfering with events involved in 
NLRP3 conformational changes secondary to activation or binding 
to ASC (18). Again, 8-month-old female mice were treated with ve-
hicle or 16673-34-0 (100 mg/kg per day, ip) for 12 weeks. No signif-
icant changes were observed in body weight between groups either 
(fig. 8A). Notably, AMH, FSH, and E2 serum levels were not signifi-
cantly different between both groups (fig. S8, B to D). Last, there 
were also no differences in pregnancy rate and mean litter size (fig. 
S8, E and F).
DISCUSSION
Aging of the world population is as undeniable as its profound 
health and economic consequences (19). The increased average age 
at which women have children and the consequent increase in 
problems related with fertility are the principal causes that lead to 
an increase in the demand for assisted reproduction technologies 
(20, 21). However, the molecular mechanisms of ovarian aging, which 
may provide new clues for protection from aging-specific female 
reproductive decline, are still not well understood. Inflammation 
and autophagy are highly associated with aging, and many rejuve-
nation strategies rely on anti-inflammatory and autophagy induc-
tions (22). Increased systemic inflammation is commonly associated 
with metabolic alterations, including the appearance of increased 
adiposity, insulin resistance, and dyslipidemia, responses that are 
likely critical determinants in the shortening of life span and overall 
health. Many of these metabolic alterations have been associated 
with NLRP3 inflammasome activation (1, 9, 10, 23). However, little 
is known about the role of NLRP3 during female aging and fertility. 
Effective fertility requires a fine balance between pro- and anti- 
inflammatory mediators and reproductive hormones. Inflammation 
Nlrp3−/− old vs. WT old 
Nlrp3−/−WT
A B
Up-regulated
Down-regulated
Fig. 4. Transcriptional changes in ovaries from old WT and Nlrp3−/− mice. (A) The most enriched KEGG pathways are shown for both overexpressed (691) and under-
expressed genes (762). Differentially expressed genes were extracted with fold change > 2 and P < 0.05 (Bea). GeneRatio shows the relative frequency of genes that be-
long to that pathway. (B) Heatmap that shows the expression values (z scores) of differently expressed protein-coding genes involved in the following pathways: cell 
cycle, oocyte meiosis, and progesterone-mediated oocyte maturation, separated by the three replicates of aged WT and Nlrp3−/−.
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has been associated with female infertility and metabolic dysfunc-
tion, suggesting that early and chronic inflammation may trigger 
early menopause, which is associated with the cessation of the ovar-
ian function (24). In the current study, we provide evidence showing 
that the NLRP3 inflammasome is an important determinant of fer-
tility in human and aged female mice. We show that the expression 
of NLRP3 and other components of the complex rapidly increase in 
the ovary during aging and human GCs, in a human condition of 
accelerated ovarian aging. Moreover, we show the localization of 
NLRP3 protein within oocytes and GCs throughout follicular 
development, which is consistent with the localization of inflamma-
tory protein (6). NLRP3 was also expressed in the glandular epithe-
lium of the uterus. Since inflammation has been implicated in the 
regulation of uterine endometrium, reduction of growth, and viability 
of preimplantation stage embryos leading to miscarriages (25), 
the role of NLRP3 in the uterus during aging will need to be explored.
Inflamm-aging, the long-term result of the chronic stimulation 
of the innate immune system with continuous damage during the 
aging process, has been associated with patients with DOR in which 
levels of several cytokines are increased (26). Our data reveal in-
creased levels of TNF- in serum samples with no significant changes 
in IL-1 and IL-18. mRNA expression levels of NLRP3 were in-
creased in patients’ GCs. Furthermore, the reproductive advantage 
of Nlrp3−/− mice compared with WT mice was corroborated by the 
transcriptomic analysis, which showed that different pathways as-
sociated with meiosis, oocyte growth, and maturation were im-
proved in Nlrp3 null mice. According to this, NLRP3 has a specific 
role in the ovarian aging process. Our data also demonstrate that 
the genetic inhibition of NLRP3, but not in ASC, enhances ovula-
tion and pregnancy rates and improve ovarian endocrine function 
in an apparently inflammasome-independent manner, whereas ova-
ries from Nlrp3 gain-of-function mutant mice have hormone levels 
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consistent with reduction of fertility. These data suggest that NLRP3 
has differential roles in innate immunity and reproduction. Our data 
are consistent with previous reports showing the preventive role of 
Nlrp3 deletion but not caspase-1/11 or ASC in other tissues and pa-
thologies (27, 28). Furthermore, Nlrp3−/− female mice showed in-
creased inflammatory cytokine levels in the ovary; however, despite 
this, ovarian aging was prevented by Nlrp3 deletion, which indi-
cates an inflamm-aging–independent role of NLRP3.
Nlrp3 ablation also showed an increase in autophagy in aged 
ovaries consistent with previous data in other tissues (9, 29). It is 
known that autophagy efficiency is reduced during aging in many 
tissues (30). The autophagy pathway has been linked to the preser-
vation of the oocyte longevity by maintaining the endowment of 
female germ cells before the establishment of primordial follicle 
(PMF) pools in the ovary (13, 31). This mechanism may be the key 
to the improvement of ovarian life span induced by the inhibition of 
NLRP3. Furthermore, the support of many of the strategies has 
been shown to improve the reproductive aging and ovarian life span 
through the improvement of autophagy (31, 32, 33).
The present study further demonstrates a metabolic regulatory 
effect of the NLRP3 inflammasome in females in the reproductive 
hormone during the equivalent perimenopause period in female 
mice. Mice are sexually mature by 3 to 6 months of age, and the 
human endocrine equivalent of human perimenopause is 8 to 
9 months of age (34). During this biological time frame, many bio-
chemical changes mark reproductive aging, including increased 
levels of estrogen, FSH, and metabolic and inflammatory factors 
(35, 36). Our middle- aged Nlrp3−/− female mice showed the hor-
monal status of the perimenopause stage, decreased risk factors of 
age-related diseases. Female KO mice showed improved glucose 
tolerance, a nonsignificant reduction of leptin levels, and an in-
crease of adiponectin levels.
Several NLRP3 inhibitors have been identified and studied in 
different disease states. While several of these inhibitors have been 
shown to have a specific direct action on NLRP3, others have indi-
rect inhibitory effects (18). MCC950 is a specific small-molecule 
inhibitor of this inflammasome, although the molecular mecha-
nisms of action of this compound have not been fully elucidated 
(18). Our study shows that MCC950 improves fertility in female 
middle-aged mice similar to Nlrp3 KO mice.
We acknowledge the limitations of using patients with DOR 
only. The use of GCs from healthy women with different age during 
the biological aging could corroborate our hypothesis. However, it 
is difficult to obtain samples from healthy individuals at different 
ages for ethical reasons. On the other hand, we have studied the ef-
fect of the ablation or constitutive activation of NLRP3 where we 
cannot separate local out of the systemic effects. Thus, future inves-
tigations should focus on ovarian-specific, ovarian-restricted manip-
ulation of the inflammasomes.
In conclusion, NLRP3 inhibition attenuates ovarian aging and 
prolongs fertility in female mice. NLRP3 ablation improved hor-
monal and metabolic characteristics related to female reproductive 
aging, improved autophagy, and reduced apoptosis Therefore, pre-
vention of the ovarian aging process through multiple mechanisms 
by NLRP3 inhibition could attenuate the reproductive aging in fe-
male mice. Taking into account the observed increased expression 
of NLRP3 in the ovary during normal aging and in patients with 
DOR, NLRP3 inhibition offers a promising therapeutic target to 
maintain female fertility during aging.
MATERIALS AND METHODS
Ethical statements
For the human study, written informed consent and the approval of 
the Research Ethics Committee of the Virgen Macarena University 
Hospital, Seville, Spain were obtained, according to the principles of 
the Declaration of Helsinki. Animal studies were performed in ac-
cordance with European Union guidelines (2010/63/EU) and the 
corresponding Spanish regulations for the use of laboratory animals 
in chronic experiments (RD 53/2013 on the care of experimental 
animals). All experiments were approved by the local institutional 
animal care committee.
Patients
The study consisted of 20 women from our fertility clinic diagnosed 
with DOR according to the Bologna criteria (37) and 20 healthy 
women from our oocyte donation program. Inclusion criteria were 
healthy women younger than 40 years old, without a previous preg-
nancy at term, an abnormal ovarian reserve test (antral follicle 
count of less than five to seven follicles or FSH >10 mIU/ml and E2 
>60 pg/ml on day 3 of the cycle), and previously characterized poor 
ovarian response stimulation cycle [three or less oocytes with a con-
ventional stimulation protocol and E2 <500 pg/ml on the day hu-
man chorionic gonadotropin (hCG) was given]. Exclusion criteria 
were a significant ongoing medical problem. Healthy controls were 
younger than 35 years old, with antral follicle counts >10 follicles, 
serum levels of FSH <10 IU/ml, and serum E2 <60 pg/ml on day 3 
of the cycle and no previous medical history of infertility. All pa-
tients included in the study were associated with idiopathic ovarian 
insufficiency without antecedents of iatrogenic or gonadotoxic events.
All patients and controls had taken no drugs or vitamin/nutritional 
supplements during the 3 weeks before to the collection of blood 
samples. Clinical data were obtained in the fertility clinic of Instituto 
de la Biología de la Reproducción Humana (INEBIR) following the 
committee opinion advice of the Sociedad Española de Fertilidad 
(www.sefertilidad.net), the European Society of Human Reproduction 
and Embryology (www.eshre.eu), and the American Society for 
Reproductive Medicine (www.asrm.org).
GC isolation
Mural GCs were obtained from 20 patients with DOR and 20 healthy 
women after oocyte retrieval from 20 patients undergoing in vitro 
fertilization (IVF) treatment at INEBIR. Ovarian stimulation was ac-
complished using a short protocol strategy combining gonadotropin- 
releasing hormone antagonist short protocol (Cetrorelix acetate, 
Cetrotide, Merck Serono Europe Limited, Spain), recombinant FSH 
(GONAL-f 75 UI, Merck Serono Europe Limited, Spain), urinary 
human menopausal gonadotropin (HMG-Lepori 75 UI, Angelini 
Farmacéutica, S.A, Spain) and recombinant hCG (Ovitrelle 250 mi-
crograms, Merck Serono Europe Limited, Spain), or leuprorelin ac-
etate (Procrin 1 mg/0.2 ml, AbbVie Spain S.L.U.) to initiate final 
follicle maturation.
Preparation of IVF-GCs for culture started when the medical 
team decided to administer hCG trigger to optimize the final oocyte 
maturation. Thirty-six hours before oocyte retrieval, light paraffin 
culture oil and filtered in sterility (OVOIL culture oil, Vitrolife, 
Sweden) are added to a petri dish (60 mm by 15 mm dish, Nunclon 
Delta) and preequilibrated in a CO2 incubator at +37.3°C and 6% 
CO2. Twenty-four hours before oocyte retrieval, culture medium 
drops (G-IVF PLUS, Vitrolife, Sweden) were prepared in a petri 
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dish and covered with the preequilibrated oil; the medium drops 
contain oocyte-granulosa clusters obtained during oocyte retrieval. 
In addition to culture medium preparation, G-MOPS PLUS (Vitrolife, 
Sweden) medium aliquots were prepared and used to wash and iso-
late GCs during oocyte retrieval; two tubes with 8 ml of G-MOPS 
PLUS on each one and one tube with 1 ml of G-MOPS PLUS. Tubes 
were stored in the CO2 incubator and were firmly closed to prevent 
pH and osmolarity changes.
The day of oocyte retrieval, the embryologist team worked 
on a safety work hood with a heated surface (K-SYSTEMS IVF 
Workstations, CooperSurgical Medical Devices) with all the labora-
tory material needed to isolate the oocyte-cumulus complexes and 
GC clusters: 60-mm embryo-tested petri dishes and sterile glass 
Pasteur pipettes (150-mm Short Soda Glass Pasteur, Hunter Scien-
tific). During oocyte retrieval, the gynecologist aspirated the follic-
ular fluid of each follicle and deposited it in sterile conical tubes 
(Falcon 15-ml Polystyrene Centrifuge Tube) previously heated in a 
thermoblock; all the conical tubes were transferred to the embryo 
laboratory in a thermoblock to ensure a constant temperature once 
the oocytes were aspirated. Simultaneously, the embryologist re-
ceived the tubes from the operating room, and their contents were 
deposited in 60-mm preheated petri dishes on the safety work hood. 
Once the cumulus-oocytes were identified under the microscope, 
they were transferred to a petri dish containing 8 ml of G-MOPS 
PLUS to be washed from blood cells and follicular fluid with sterile 
glass Pasteur pipettes. At the end of oocyte retrieval, every cumulus- 
oocyte complex was transferred to the culture medium drops previ-
ously equilibrated in the CO2 incubator. At the same time, free 
granulose cells were identified in the follicular fluid and transferred 
to the 1-ml G-MOPS PLUS tube. These tubes were centrifuged at 
3200 rpm for 5 min; the supernatants were discarded, and compact 
pellets of granulose cells were obtained. The pellets are resuspended 
in 0.5 ml of RNAlater solution (RNAlater, Sigma-Aldrich) to stabi-
lize RNA and prevent its degradation and stored in a freezer at −20°C.
Animals
For all experiments, only female mice were used. Young and old 
Nlrp3−/− and Asc−/− mice [C57BL/6J background, provided by 
B. Ryffel and originally generated and characterized in the laborato-
ry of J. Tschopp (38)] and WT/Nlrp3+/+/Asc+/+ littermate controls 
(also on C57BL/6J background), weighing 25 to 30 g, were main-
tained on a regular 12-hour light/12-hour dark cycle. All groups 
had ad libitum access to their prescribed diet and water throughout 
the whole study. Body weight was monitored weekly. Animal rooms 
were maintained at 20° to 22°C with 30 to 70% relative humidity.
To generate gain-of-function NLRP3 in myeloid cells and WT 
littermate controls, we bred NOMID mice (Nlrp3D301NneoR Jax 
#017971) with lysozyme M–Cre (Lyz2tm1(cre)Ifo/J Jax#004781; 
C57BL/6J background). Ovaries were harvested from 2-week-old 
mice and were immediately frozen in liquid nitrogen. The weights 
of WT littermate control mice were in the range of 6 to 7 g, and 
NOMID mice were in the range of 3 to 4 g, consistent with previous 
reports.
For all experiments with NLRP3 inhibitors, female C57BL6/J 
mice (to maintain the comparative background) from the Jackson 
laboratory were maintained on a regular 12-hour light/12-hour 
dark cycle at 20° to 22°C. Treatments were started at 8 months of 
age after randomization into four groups. This study was distributed 
in two substudies: vehicle versus MCC950 and vehicle versus 
16673-34-0. These groups correspond to the following treatment: 
(i) standard diet with intraperitoneal vehicle (saline) treatment 
(vehicle group) from Teklad Global 14% Protein Rodent Mainte-
nance Diet, Harlan Laboratories (carbohydrate:protein:fat ratio of 
48:14:4 percent of kcal), (ii) standard diet with MCC950 treatment 
(MCC950 group), (iii) vehicle group, and (iv) standard diet with 
16673-34-0 treatment (16673-34-0 group). MCC950 was adminis-
tered by intraperitoneal route at previously characterized doses: 
20 mg/kg daily and 16673-34-0 by intraperitoneal route at 100 mg/kg 
daily (39, 40). All groups had ad libitum access to their prescribed 
diet and water throughout the study. Body weight and food intake 
were monitored weekly.
Reagents
Monoclonal antibodies specific for Beclin 1 and p62 were purchased 
from Sigma-Aldrich (Saint Louis, USA). The anti–glyceraldehyde- 
3-phosphate dehydrogenase monoclonal antibody was acquired 
from Calbiochem-Merck Chemicals Ltd. (Nottingham, UK). Last, 
anti–Bcl-2, anti-Bax, anti-ATG12, and anti–MAP-LC3 antibodies 
were obtained from Santa Cruz Biotechnology. Anti-AMH anti-
body was obtained from Abbexa (Cambridge, UK). NLRP3 inhibi-
tors MCC950 and 16673-34-0 were obtained from Sigma-Aldrich 
(Saint Louis, USA) and R&D Systems (Minneapolis, USA), respec-
tively. A cocktail of protease inhibitors (cOmplete Protease Inhibitor 
Cocktail) was purchased from Boehringer Mannheim (Indianapolis, 
IN). The Immun-Star horseradish peroxidase (HRP) substrate kit 
was obtained from Bio-Rad Laboratories Inc. (Hercules, CA).
Real-time quantitative polymerase chain reaction
The expression of the NLRP3 gene was analyzed by SYBR Green 
quantitative polymerase chain reaction (PCR) of mRNA extracted 
from GCs according to the previously described methodology (41). 
Briefly, total cellular RNA was purified from the cells by the TRIsure 
method (Bioline, London, UK). RNA concentration was determined 
spectrophotometrically. RNA samples were subsequently reverse- 
transcribed to cDNA using the QuantiTect Reverse Transcription 
Kit (QIAGEN, Hilden, Germany). PCR amplifications were con-
ducted with primers targeting NLRP3 (NM_004895.4) and -actin, 
used as an internal control. Thermal cycling conditions used were 
denaturation at 95°C for 20 s, 40 cycles of priming at 54°C for 20 s, 
and elongation at 72°C for 20 s. All reactions were performed in 
duplicate, and reaction mixes without RNA were used as negative 
controls in each run. Absence of contaminating genomic DNA was 
confirmed by setting up control reactions with RNA that had not 
been reverse transcribed. Fold changes in the expression of genes of 
interest were calculated using the Ct method.
Mouse longevity study
The longevity study was previously described (9). Briefly, WT and 
Nlrp3−/− female mice (C57BL/6J background), weighing 25 to 30 g, 
were maintained on a regular 12-hour light/12-hour dark cycle. 
Mice were housed in groups of four to eight same-sex littermates 
under specific pathogen–free conditions. Individuals were moni-
tored daily and weighed monthly but were otherwise left undis-
turbed until they died. Survival was assessed using male and female 
mice, and all animals were dead by the time of this report. Kaplan- 
Meier survival curves were constructed using known birth and 
death dates, and differences between groups were evaluated using 
the log-rank test. A separate group of female mice were sacrificed 
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at different ages between 4 and 12 months to study ovaries (histology 
and Western blots).
Breeding
WT, Nlrp3−/−, and Asc−/− female mice were individually caged with 
a WT male mice of confirmed fertility for a period of 1 month. Fe-
male mice were monitored and weighed daily. Female mice that 
gained 3 g of weight were considered pregnant and sacrificed. The 
number of fetuses per female was quantified.
Glucose tolerance test
Glucose tolerance tests were performed by fasting the mice over-
night for 16 hours and then injecting glucose (1 g/kg) intraperitone-
ally. Glucose measurements were performed using a Bayer Contour 
blood glucose meter and test strips.
Serum AMH measurement
Blood samples were taken from the heart by cardiac puncture, pref-
erably from the ventricle, and serum samples were extracted and 
kept at −80°C until use. Measurements were performed using 
enzyme-linked immunosorbent assay (ELISA) according to the 
manufacturer’s instructions (Beckman Coulter).
Leptin and adiponectin
Serum levels of leptin and adiponectin were assayed in duplicate 
using commercial ELISA kits (R&D Systems, Minneapolis, USA).
Serum biomarkers
Serum levels of glucose, triglycerides, cholesterol, uric acid, aspartate 
aminotransferase, alanine aminotransferase, and creatine kinase were 
assayed using commercial kits (Randox Laboratories, Antrim, UK).
Immunoblotting
Western blotting was performed using standard methods. After 
protein transfer, the membrane was incubated with various primary 
antibodies diluted at 1:1000 and then with the corresponding sec-
ondary antibodies coupled to HRP at a 1:10,000 dilution. Ponceau S 
staining was selected as a loading control. Specific protein complexes 
were identified using an Immun-Star HRP substrate kit (Bio-Rad 
Laboratories Inc., Hercules, CA, USA).
Histological study
After anesthesia of mice, ovaries were excised and immediately 
placed in 10% neutral-buffered formalin. The ovaries were embed-
ded in paraffin, serially sectioned at a thickness of 5 m, and stained 
with hematoxylin and eosin. Each section was scanned for morpho-
logical analysis, and every fifth section was used to quantify the total 
number of follicles classified by states: the number of PMF and pri-
mary, secondary, and antral follicles (42). The middle section of 
each ovary was used for a representative visual comparison in the 
figure.
Immunostaining
Ovaries were dissected, fixed in 4% paraformaldehyde, and embed-
ded in paraffin. We baked 4-m sections at 60°C for 1 hour, depar-
affinized in xylenes, and rehydrated into phosphate-buffered saline 
(PBS). Antigen retrieval was done in boiling citrate buffer [10 mM 
sodium citrate (pH 6.0)] for 15 min. Sections were blocked in PBS 
containing 2% bovine serum albumin + 0.05% Triton X-100 and 5% 
normal donkey serum for 1 hour at room temperature and then in-
cubated with primary antibodies (NLRP3/NALP3 Antibody, Novus 
Biological) diluted in blocking solution overnight at 4°C. After wash-
ing with PBS containing 0.2% Triton X-100, they were incubated 
with fluorescent secondary antibody (Alexa Fluor 488, Invitrogen) 
in blocking solution for 1 hour at room temperature, followed by PBS 
washes. The sections were then counterstained with ProLong Gold 
Antifade reagent with 4′,6-diamidino-2-phenylindole (Invitrogen).
Transcriptome analysis
Transcriptomic analysis was previously described (9). Briefly, we 
used the Affymetrix Clariom S assay mouse. The raw data were an-
alyzed by the Affymetrix software Transcriptome Analysis Console. 
Expression values were normalized by Signal Space Transformation– 
Robust Microarray Analysis, and the mutant mice were compared 
with WT using three replicates for every analysis. Then, fold change 
and P value were calculated for every gene by an unpaired one-way 
test (single factor) using the NMath package. A gene was considered 
differentially expressed when it had a fold change equal or higher 
than 2 and a P value equal or lower than 0.05 using Fisher’s exact 
test. Then, gene names of protein-coding genes were mapped to 
Ensembl identifiers using BioMart (https://pubmed.ncbi.nlm.nih.
gov/19617889/), and functional enrichment was made using KEGG 
Pathway as annotation source with the R libraries biomaRt and 
clusterProfiler and a P value threshold of 0.05.
Statistics
The evaluation of normality was performed using the Shapiro-Wilk 
test. Then, statistical differences among the different groups were 
measured using either an unpaired Student’s t test or one-way anal-
ysis of variance (ANOVA) when appropriate, with Tukey’s post hoc 
test when appropriate. All data are shown as means ± SD. A P value 
of ≤0.05 was considered statistically significant. For these statistical 
analyses, we use Prism software version 5.0a (GraphPad, San Diego, 
CA). Asterisks in the figures represent the following: *P < 0.05, 
**P < 0.01, and ***P < 0.001.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/7/1/eabc7409/DC1
View/request a protocol for this paper from Bio-protocol.
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